// App-Quantinova.ai

POS1040 (2021) : IMPLEMENTATION OF THE OMERACT PSAMRIS IN A PHASE IIB, RANDOMISED PLACEBO-CONTROLLED STUDY OF ABATACEPT IN PSORIATIC ARTHRITIS

Researchers

Presenter

  • M. stergaard

Principal Investigators

  • P. Bird

  • C. Pachai

  • S. Du

  • C. Wu

  • J. Landis

  • T. Fuerst

  • H. A. Ahmad

  • S. Connolly

  • P. G. Conaghan

Medical Centers

  • Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup Copenhagen Center for Arthritis Research, Copenhagen, Denmark

  • University of Copenhagen, Dept. of Forensic Medicine, Copenhagen, Denmark

  • University of New South Wales (NSW), Division of Medicine, Sydney, Australia

  • BioClinica, Inc., Medical and Scientific Affairs, Newark, United States of America

  • Bristol Myers Squibb, Medical Immunology, Princeton, United States of America

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

Locations

  • Denmark

  • Australia

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT00534313

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved